The Funds objective is to outperform global equity markets over a long-term period (minimum of five years) by investing in international equities of companies involved in the medical technology ecosystem while integrating ESG criteria in the investment process. The Fund is invested for at least 75% of its assets in equity and equity equivalent securities of any country without constraints of capitalisation.